RT Book, Section A1 Howland, Mary Ann A1 Smith, Silas W. A2 Nelson, Lewis S. A2 Howland, Mary Ann A2 Lewin, Neal A. A2 Smith, Silas W. A2 Goldfrank, Lewis R. A2 Hoffman, Robert S. SR Print(0) ID 1163002685 T1 Glucagon T2 Goldfrank's Toxicologic Emergencies, 11e YR 2019 FD 2019 PB McGraw-Hill Education PP New York, NY SN 9781259859618 LK accessemergencymedicine.mhmedical.com/content.aspx?aid=1163002685 RD 2024/10/13 AB The traditional role of glucagon was to reverse life-threatening hypoglycemia in patients with diabetes unable to receive dextrose in the outpatient setting. However, in clinical toxicology, glucagon is used early in the management of β-adrenergic antagonist and calcium channel blocker toxicity to increase heart rate, contractility, and blood pressure by increasing myocardial cyclic adenosine monophosphate (cAMP) via a non–β-adrenergic receptor mechanism of action. The use of glucagon is based primarily on animal studies as well as human case series and case reports. The effects of glucagon are often transient.